231 related articles for article (PubMed ID: 15983462)
21. Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652.
Xing J; Ma J; Zhang P; Fan X
Eur J Pharmacol; 2010 Mar; 630(1-3):1-9. PubMed ID: 19903464
[TBL] [Abstract][Full Text] [Related]
22. Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656.
Scholz EP; Zitron E; Kiesecker C; Thomas D; Kathöfer S; Kreuzer J; Bauer A; Katus HA; Remppis A; Karle CA; Greten J
Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):666-75. PubMed ID: 16926094
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.
Zitron E; Kiesecker C; Scholz E; Lück S; Bloehs R; Kathöfer S; Thomas D; Kiehn J; Kreye VA; Katus HA; Schoels W; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):146-56. PubMed ID: 15322737
[TBL] [Abstract][Full Text] [Related]
24. Blockade of the human ether-a-go-go-related gene potassium channel by ketanserin.
Tu DN; Zou AR; Liao YH; Du YM; Wang XP; Li L
Sheng Li Xue Bao; 2008 Aug; 60(4):525-34. PubMed ID: 18690396
[TBL] [Abstract][Full Text] [Related]
25. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
Melgari D; Brack KE; Zhang C; Zhang Y; El Harchi A; Mitcheson JS; Dempsey CE; Ng GA; Hancox JC
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25911606
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
[TBL] [Abstract][Full Text] [Related]
29. Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels.
Kiesecker C; Alter M; Kathöfer S; Zitron E; Scholz EP; Thomas D; Kreuzer J; Katus HA; Bauer A; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jun; 373(3):212-20. PubMed ID: 16736158
[TBL] [Abstract][Full Text] [Related]
30. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
31. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
32. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
33. Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels.
Rodriguez-Menchaca A; Ferrer-Villada T; Lara J; Fernandez D; Navarro-Polanco RA; Sanchez-Chapula JA
J Cardiovasc Pharmacol; 2006 Jan; 47(1):21-9. PubMed ID: 16424781
[TBL] [Abstract][Full Text] [Related]
34. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
35. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
36. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
Scholz EP; Zitron E; Kiesecker C; Lueck S; Kathöfer S; Thomas D; Weretka S; Peth S; Kreye VA; Schoels W; Katus HA; Kiehn J; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):404-14. PubMed ID: 14557918
[TBL] [Abstract][Full Text] [Related]
37. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant.
Al-Moubarak E; Shiels HA; Zhang Y; Du C; Hanington O; Harmer SC; Dempsey CE; Hancox JC
Cell Mol Life Sci; 2021 Dec; 78(23):7899-7914. PubMed ID: 34727194
[TBL] [Abstract][Full Text] [Related]
39. Interaction of ropivacaine with cloned cardiac Kv4.3/KChIP2.2 complexes.
Friederich P; Solth A
Anesthesiology; 2004 Dec; 101(6):1347-56. PubMed ID: 15564942
[TBL] [Abstract][Full Text] [Related]
40. Open channel block of HERG K(+) channels by vesnarinone.
Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]